Follow Hims & Hers Health to never miss an important update.
Hims & Hers has reached a deal with Eli Lilly to provide patients access to brand-name weight loss medications like Zepbound. This is a major shift for the company, which has recently focused on selling compounded versions of these drugs, custom-mixed alternatives made by pharmacies when brand-name versions are in short supply.
By adding the official Lilly medicines at set prices, Hims & Hers is moving closer to being a mainstream healthcare provider rather than just a source for alternatives. This helps protect the business if the government eventually limits the sale of compounded drugs once the national shortage of brand-name versions ends. It also gives the company a more stable, long-term path to keep growing its weight loss business.
Source: PRNewsWire
Hims & Hers added four new partners, Grüns, Medjet, Tonal, and Viome, to its benefits program. This program gives subscribers access to outside health and fitness services, such as home gym equipment and health testing, alongside their prescriptions. While these partnerships help keep subscribers engaged with the platform, they are a small part of the overall business. The real value for the company remains its ability to sell its own personalized treatments and medications.
Source: Business Wire
Hims & Hers will share its latest results in about a week. Analysts expect the company to earn roughly 6 cents per share. This update is particularly important for tracking how quickly its new weight loss program is growing. We will be watching to see if the company can maintain its profit margins as it scales these newer treatments alongside its core hair loss and sexual health business.
Hims & Hers is expanding its men's health business by adding new ways for customers to take testosterone replacement therapy. This is the largest addition to this category since it launched last year, offering both injections and pills through its network of licensed doctors.
This move follows the company's successful playbook of taking a common medical need and making it easier to access through a digital subscription. By adding more ways to take the treatment, Hims can reach more of the estimated 20 million men with low testosterone and keep them on the platform longer. This helps the company grow beyond its original focus on hair loss and sexual health into a broader healthcare brand.
Source: Business Wire
Hims & Hers is facing a securities class action lawsuit following a federal complaint from the FTC, the agency that protects consumers from unfair business practices. The lawsuit claims the company and its leaders misled investors about its business conduct, which led to a drop in the stock price when the investigation was revealed.
These types of lawsuits are common after a federal agency takes action against a company. While the lawsuit itself is in the early stages, the underlying FTC investigation is the more important thing to watch. If the government finds serious misconduct in how the company signs up or treats customers, it could lead to fines or forced changes to how Hims & Hers operates.
Source: GlobeNewsWire
Management has struggled to set a reliable bar lately, with several large misses suggesting the business is becoming harder to forecast as it scales into new categories.
| Expectation | |
|---|---|
| EPS | $0.06 |
| Revenue | $893M |
Follow Hims & Hers Health to get the latest and most important updates.
Follow HIMS